CAMBRIDGE, MASS.--(Business Wire / Korea Newswire)--ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced the appointment of Paul Perreault to its Board of Directors, effective December 5, 2023. Mr. Perreault most recently served as Chief Executive Officer of CSL and brings over 40 years of leadership experience across the biotechnology industry.

“Paul is a distinguished industry executive recognized for his extensive track record in drug development and was integral to the growth of CSL to become an international leader in the field. His leadership and extensive knowledge of the biotech industry will be an invaluable addition to our company as we continue to build our portfolio of novel RNA medicines,” said Amit D. Munshi, Chief Executive Officer of ReNAgade. “We are pleased to welcome Paul to the ReNAgade team and look forward to his contributions.”

“I am thrilled to join ReNAgade at this exciting time for the company,” said Mr. Perreault. “ReNAgade is led by a world-class executive team, and its innovative technologies have the potential to drive the field of RNA medicines forward on an unprecedented scale in the coming years.”

Mr. Perreault brings more than 40 years of experience in the global biotechnology and pharmaceutical industries, most recently as CEO and Managing Director of CSL. Within his 25-year career with CSL, he was responsible for operations in more than 40 countries, including major manufacturing sites in the U.S., Switzerland, Germany and Australia, and an extensive network of plasma collection centers throughout North America and Germany. He previously served in senior leadership roles at various companies in the space including Wyeth, Centeon, Aventis Bioservices and Aventis Behring, and served on the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA). In 2019, Mr. Perreault was included in Harvard Business Review’s CEO 100 List and recognized as one of the best performing CEOs in the world. He earned his B.S. in Psychology from the University of Central Florida and completed advanced business management training at Kellogg School of Management and Wharton School of the University of Pennsylvania.

About ReNAgade Therapeutics

ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.

To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.

ReNAgade Therapeutics—RNA Without Limits

For more information about the company, its technologies, and its leadership, visit www.renagadetx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20231205970464/en/

Website: https://renagadetx.com/ View Korean version of this release Contact ReNAgade Therapeutics
Investor Relations
Argot Partners
Emily Brabbit
(212) 600-1902
[email protected]

Media Relations
Argot Partners
Sarah Sutton
(212) 600-1902
[email protected]
This news is a press release from the provider.
Korea Newswire is committed to verifying the transparency of providers and eliminating content errors.
You can receive press releases from this company or in industries of interest via email and RSS for free. Subscribe> News provided byReNAgade Therapeutics Distribution Channel Health Pharmaceutical Biotechnology Personnel anouncement Overseas